Inspire Medical announced today that it received expanded FDA approval for its Inspire IV and V neuromodulation systems.
Electrical transcutaneous neuromodulation (eTNM) of the peroneal nerve led to fewer side effects compared with solifenacin (Vesicare) in the treatment of overactive bladder, a randomized trial showed.
Neuromodulation is entering a new era, moving beyond broad, high-power stimulation toward targeted, adaptive, and energy-efficient approaches. While ...
Cognito Therapeutics announced today that it entered into a collaboration with Ochsner Health to advance new approaches to ...
Lewes, Delaware, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The Global Neuromodulation Market Size is projected to grow at a CAGR of 9.27% from 2026 to 2032, according to a new report published by Verified ...
6d
Avation Medical Announces Manish Vaishya, PhD as Chief Executive Officer; Closes Series D Financing
Avation strengthens leadership and secures funding to scale its innovative digital health and neuromodulation platform ...
Neuronoff, Inc., a clinical-stage neuromodulation company, today announced successful chronic large animal demonstration of ...
Please provide your email address to receive an email when new articles are posted on . Artificial tears have long been the first option for patients with dry eye disease, but they only offer a ...
The function of the lower urinary tract — to store and periodically eliminate urine — seems simple, but its neuronal control is complex and not fully understood, and dysfunction is common. Functional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results